(This article by rdpeng was originally published at Simply Statistics.)
It seems the sequencing company will remain independent for now.
Roche lost its bid to replace the Illumina board on Wednesday and promptly withdrew its hostile bid. Roche plays a long game, though, and has ample experience in successful hostile takeover bids for Ventana and Genentech.
Stay tuned!
Please comment on the article here: Simply Statistics
